Albireo is a rare disease company focused on the development of novel bile acid modulators to treat pediatric and adult liver diseases. Albireo’s lead product, Bylvay, was approved by the U.S. FDA as the first drug for the treatment of pruritus in all types of progressive familial intrahepatic cholestasis (PFIC), and in Europe for the treatment of PFIC. Bylvay is also being developed to treat other rare pediatric cholestatic liver diseases with a completed Phase III trial in ALGS, an ongoing Phase III study in biliary atresia, as well as Open-label Extension (OLE) studies for PFIC and ALGS. The company has also completed a Phase I clinical trial for A3907 to advance development in adult cholestatic liver disease, with IND-enabling studies progressing with A2342 for viral and cholestatic liver disease. Albireo was spun out from AstraZeneca in 2008 and is headquartered in Boston, Massachusetts, with its key operating subsidiary in Gothenburg, Sweden. For more information on Albireo, please visit www.albireopharma.com.

albireopharma.com

Albireo

Ipsen SAS is a global biopharmaceutical group focused on innovation and specialty care. The company provides transformative medicines to patients worldwide, with a strong emphasis on oncology and rare diseases. Ipsen is listed on Euronext Paris and is known for its commitment to research and development.

www.ipsen.com

Boulogne-Billancourt, Ile De France, France

Ipsen To Acquire Albireo Accelerating Growth In Rare Disease With Treatments For Several Pediatric Liver Diseases

Description

Company Information

Related People

M&A Insights

Ipsen To Acquire Albireo Accelerating Growth In Rare Disease With Treatments For Several Pediatric Liver Diseases

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Related People

M&A Insights

Company Information